This site is intended for health professionals only
Monday 16 July 2018
Share |

CE Mark for JuniorSTAR®

Related articles

First clinically approved diabetic moisturiser for use on the entire foot including between toes now available in UK
Additional study demonstrates cost impact of hypoglycaemia in the hospital setting
Sanofi (EURONEXT: SAN and NYSE: SNY) has announced at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, the CE Mark of JuniorSTAR®, a new half unit insulin reusable pen that can be used with Lantus® (insulin glargine), Apidra® (insulin glulisine) or Insuman® (recombinant human insulin).

Ads by Google